Not exact matches
Alnylam Pharmaceuticals stock plummeted 45 percent after the therapeutics company announced it was discontinuing its
development of revusiran, a therapeutic aimed at treating hereditary ATTR
amyloidosis.
Proclara Biosciences Presents Preclinical Data Supporting the
Development of GAIM - Based Therapies for Peripheral Amyloidoses at the 16th International Symposium on
Amyloidosis March 28, 2018
Proclara Biosciences Presents Preclinical Data Supporting the
Development of GAIM - Based Therapies for Peripheral Amyloidoses at the 16th International Symposium on
Amyloidosis
High fibre diets also contain various fatty acids such as the short chain fatty acids (SCFA) and the understanding
of synergistic effects
of SCFA and phytosterols in glucose regulation and cholesterol homeostasisis important to our understanding
of diet, lifestyle and drugs in relation to peripheral
amyloidosis and gene expression that play an early role in the
development of AD.